Table 2 Treatment Received
From: High rate of bleeding and arterial thrombosis in COVID-19: Saudi multicenter study
| Treatment |
Overall n = 636 n (%) |
Non-ICU n = 530 n (%) |
ICU n = 106 n (%) | p-value |
|---|---|---|---|---|
| Mechanical prophylaxis | 6 (0.94) | 3 (0.57) | 3 (2.8) | 0.016 |
| Pharmacological prophylaxis | 573 (90.0) | 468 (88.3) | 105 (99.0) | 0.0007 |
| DOAC during admission | 9 (1.4) | 7 (1.3) | 2 (1.8) | 0.649 |
| Antiplatelet | 82 (12.9) | 62 (11.7) | 20 (19.2) | 0.037 |
| Enoxaparin Dose | ||||
| 40 mg OD | 377 (59.2) | 332 (62.6) | 45 (42.4) | < 0.0001 |
| 40 mg BD | 35 (5.5) | 18 (3.4) | 17 (16.0) | |
| 30 mg OD | 7 (1.1) | 3 (0.57) | 4 (3.7) | |
| 30 mg BD | 2 (0.31) | 0 | 2 (1.8) | |
| Full dose | 28 (4.4) | 20 (3.7) | 8 (7.5) | |
| Other dose | 24 (3.7) | 17 (3.2) | 7 (6.6) | |
| Unfractionated Heparin Dose | ||||
| 5000 TID | 41 (6.4) | 23 (4.3) | 18 (16.9) | < 0.0001 |
| 5000 BID | 77 (12.1) | 62 (11.7) | 15 (14.1) | |
| Full dose | 11 (1.7) | 6 (1.1) | 5 (4.7) | |
| Other dose | 2 (0.32) | 1 (0.19) | 1 (0.94) | |